For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Litigation settlement | - | - | 0 | 0 |
| Product revenue, net | 116,357 | 107,105 | 97,800 | 96,042 |
| Cost of goods sold | 6,323 | 6,593 | 4,263 | 7,165 |
| Research and development | 15,331 | 14,795 | 14,585 | 14,410 |
| Selling, general and administrative | 41,014 | 41,280 | 37,578 | 35,160 |
| Litigation settlement | - | 0 | - | - |
| Total operating expenses | 62,668 | 62,668 | 56,426 | 56,735 |
| Income from operations | 53,689 | 44,437 | 41,374 | 39,307 |
| Gain from sale of priority review voucher | - | 0 | - | - |
| Interest and other income, net | 7,753 | 6,695 | 6,593 | 7,468 |
| Income before income taxes | 61,442 | 51,132 | 47,967 | 46,775 |
| Income tax expense | 5,510 | -268 | -31,398 | 8,442 |
| Net income | 55,932 | 51,400 | 79,365 | 38,333 |
| Unrealized (gain) loss on available-for-sale securities | -1,577 | -437 | 657 | -158 |
| Foreign currency translation | -1,182 | 473 | -714 | 925 |
| Comprehensive income | 53,173 | 51,436 | 79,308 | 39,100 |
| Basic EPS | 1.91 | 1.768 | 2.74 | 1.33 |
| Diluted EPS | 1.83 | 1.695 | 2.66 | 1.29 |
| Basic Average Shares | 29,288,000 | 29,098,000 | 28,953,000 | 28,910,000 |
| Diluted Average Shares | 30,507,000 | 30,351,000 | 29,833,000 | 29,749,000 |
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)